BioNTech (NASDAQ:BNTX) Shares Up 4.9% – What’s Next?

BioNTech SE (NASDAQ:BNTX)’s share price rose 4.9% during mid-day trading on Tuesday . The company traded as high as $107.39 and last traded at $106.85. Approximately 392,585 shares were traded during mid-day trading, a decline of 51% from the average daily volume of 805,357 shares. The stock had previously closed at $101.87.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research report on Monday. Berenberg Bank initiated coverage on shares of BioNTech in a research report on Tuesday. They issued a “buy” rating and a $130.00 target price for the company. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $110.00 to $125.00 in a research report on Tuesday. Finally, JPMorgan Chase & Co. dropped their price objective on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a report on Monday, November 4th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.79.

BioNTech Stock Up 4.4 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $25.51 billion, a PE ratio of -50.79 and a beta of 0.26. The company has a fifty day simple moving average of $113.57 and a two-hundred day simple moving average of $97.36.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same period in the prior year, the firm posted $0.73 earnings per share. The business’s quarterly revenue was up 38.9% on a year-over-year basis. Analysts forecast that BioNTech SE will post -3.68 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently modified their holdings of BNTX. GAMMA Investing LLC raised its holdings in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after buying an additional 111 shares during the last quarter. Covestor Ltd increased its holdings in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the period. Capital International Sarl boosted its position in BioNTech by 1.3% in the first quarter. Capital International Sarl now owns 24,058 shares of the company’s stock valued at $2,219,000 after buying an additional 310 shares during the last quarter. Finally, Blue Trust Inc. raised its position in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.